Najafi Ramin Form SC 13G/A February 02, 2012

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

NOVABAY PHARMACEUTICALS, INC. (Name of Issuer)

Common Stock (Title of Class of Securities)

66987P102 (CUSIP Number)

December 31, 2011 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[]	Rule 13d-1(b)
[]	Rule 13d-1(c)
[X]	Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of the securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

Schedule

13G			Page 2 of 8 Pages
1.	Names of Reporting		
2.	Ramin Najafi, Ph.D		show of a Crown (Soc Instructions)
2.	(a)	[X]	nber of a Group (See Instructions)
	(a) (b)	[]	
3.	SEC Use Only	L J	
4.	Citizenship or Place	of Organization	
	United States of Am		
	5.		Sole Voting Power
Number of	3.		473,138
Shares	6.		Shared Voting Power
Beneficially			3,117,500
Owned by Each	7.		Sole Dispositive Power
Reporting			473,138
Person With	8.		Shared Dispositive Power
Terson with			3,117,500
9.	Aggregate Amount 3,590,638	Beneficially Own	ned by Each Reporting Person
10.	, , , , , , , , , , , , , , , , , , ,	ate Amount in R	ow (9) Excludes Certain Shares (See
	Instructions)	,	
	[]		
11.	Percent of Class Re	presented by Am	ount in Row (9)
	12.4%*		
12.	Type of Reporting F	Person (See Instru	actions)
	IN		

CUSIP No. 66987P102

^{*} Based on 28,570,963 shares of common stock outstanding as of December 31, 2011.

Schedule

Page 3 of 8 Pages

1.	Names of Reporting F	Persons	
2.	Farideh Najafi Check the Appropriat	e Box if a Member of a Group (See Instructions)	
2.		[X]	
	` '		
3.	SEC Use Only		
4.	Citizenship or Place of Organization		
	United States of Ame	rica	
N. 1 C	5.	Sole Voting Power	
Number of		0	
Shares	6.	Shared Voting Power	
Beneficially Owned by		3,117,500	
Owned by Each	7.	Sole Dispositive Power	
Reporting		0	
Person With	8.	Shared Dispositive Power	
Terson With		3,117,500	
9.	Aggregate Amount Board 3,117,500	eneficially Owned by Each Reporting Person	
10.	Check if the Aggregat	te Amount in Row (9) Excludes Certain Shares (See	
	Instructions)		
	[]		
11.	-	esented by Amount in Row (9)	
	10.9%*		
12.		rson (See Instructions)	
	IN		
* D 1 20 /	570 062 dans of	and the section of December 21, 2011	
" based on 28,3	0/0,903 snares of comm	on stock outstanding as of December 31, 2011.	

CUSIP No. 66987P102

13G

³

Schedule

13G	Page 4 of 8 Pages	
1.	Names of Reporting Persons	
2.	Najafi Family Trust	ember of a Crown (See Instructions)
۷.		ember of a Group (See Instructions)
	(a) [X] (b) []	
3.	SEC Use Only	
4.	Citizenship or Place of Organization	on
	United States of America	
Number of	5.	Sole Voting Power
Shares		0
Beneficially	6.	Shared Voting Power
Owned by	_	3,117,500
Each	7.	Sole Dispositive Power
Reporting	0	0
Person With	8.	Shared Dispositive Power
		3,117,500
9.	Aggregate Amount Beneficially O 3,117,500	wned by Each Reporting Person
10.	Check if the Aggregate Amount in	Row (9) Excludes Certain Shares (See Instructions)
11.	Percent of Class Represented by A	mount in Row (9)
	10.9%*	
12.	Type of Reporting Person (See Ins OO	tructions)
	00	

CUSIP No. 66987P102

^{*} Based on 28,570,963 shares of common stock outstanding as of December 31, 2011.

CUSIP No. 13G	66987P102	Schedule Page 5 of 8 Pages
Item 1(a).		Name of Issuer:
		NovaBay Pharmaceuticals, Inc.
Item 1(b).		Address of Issuer's Principal Executive Offices:
		5980 Horton Street, Suite 550, Emeryville, California 94608
Item 2(a).		Names of Persons Filing:
	R	amin Najafi, Ph.D., Farideh Najafi and the Najafi Family Trust
Item 2(b).		Address of Principal Business Office or, if None, Residence:
		NovaBay Pharmaceuticals, Inc. 5980 Horton Street, Suite 550 Emeryville, California 94608
Item 2(c).		Citizenship:
	afi, Ph.D. and Fa the State of Cal	arideh Najafi are citizens of the U.S.A., and the Najafi Family Trust is a trust formed under ifornia.
Item 2(d).		Title of Class of Securities:
		Common Stock
Item 2(e).		CUSIP Number:
		66987P102
Item 3. If the	is statement is fi	led pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is
	(b) [] Bank as (c) [] Insurance (d) [] Investm U.S.C 8 (e) [] An inve (f) [] An emp (g) [] A paren (h) [] A saving 1813);	or dealer registered under section 15 of the Act (15 U.S.C. 780); defined in section 3(a)(6) of the Act (15 U.S.C. 78c); ce company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); ent company registered under section 8 of the Investment Company Act of 1940 (15 0a-8); stment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); loyee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); tholding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); gs association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. the plan that is excluded from the definition of an investment company under section
	3(c)(14)	of the Investment Company Act of 1940 (15 U.S.C. 80a-3); in accordance with 8 240 13d-1(b)(1)(ii)(I):

(j) []	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k) []	Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
Not Applicable.	

CUSIP No. 66987P102 Schedule

Page 6 of 8 Pages

Item 4. Ownership.

As of December 31, 2011:

(a) Amount Beneficially

Owned:

Ramin Najafi, Ph.D. 3, 590,638 Farideh Najafi 3,117,500 Najafi Family Trust 3,117,500

(b) Percent of Class:

Ramin Najafi, Ph.D. 12.4% Farideh Najafi 10.9% Najafi Family Trust 10.9%

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote:

Ramin Najafi, Ph.D. 473,138 Farideh Najafi 0 Najafi Family Trust 0

(ii) Shared power to vote or to direct the vote:

Ramin Najafi, Ph.D. 3,117,500 Farideh Najafi 3,117,500 Najafi Family Trust 3,117,500

(iii) Sole power to dispose or to direct the disposition of:

Ramin Najafi, Ph.D. 473,138 Farideh Najafi 0 Najafi Family Trust 0

(iv) Shared power to dispose or to direct the disposition of:

Ramin Najafi, Ph.D 3,117,500 Farideh Najafi 3,117,500 Najafi Family Trust 3,117,500

The 3,590,638 shares beneficially owned by Ramin Najafi, Ph.D. includes: 3,117,500 shares held by the Najafi Family Trust; 15,252 shares held by Ramin Najafi; 305,213 option shares that can be exercised within 60 days from December 31, 2011; and 152,673 shares subject to a restricted stock award held by Ramin Najafi. The shares

beneficially owned by Farideh Najafi and the Najafi Family Trust consist solely of 3,117,500 shares held by the Najafi Family Trust. Dr. and Mrs. Najafi are co-trustees of the Najafi Family Trust.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. []

CUSIP No. 66987P102 13G	Schedule Page 7 of 8 Pages
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	Not applicable.
	classification of the Subsidiary Which Acquired the Security Being Reported on by the inpany or Control Person.
	Not applicable.
Item 8.	Identification and Classification of Members of the Group.
This filing is on behalf of pursuant to Rule 13d-1(d)	Ramin Najafi, Ph.D., Farideh Najafi and the Najafi Family Trust as members of a group
Item 9.	Notice of Dissolution of Group.
	Not applicable.
Item 10.	Certifications.
	Not applicable.

CUSIP No. 66987P102 13G Schedule

Page 8 of 8 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 2, 2012 (Date)

/s/Ramin Najafi Ramin Najafi, Ph.D.

/s/ Farideh Najafi Farideh Najafi

NAJAFI FAMILY TRUST

/s/ Ramin Najafi By: Ramin Najafi, Ph.D. Co-Trustee

/s/ Farideh najafi By: Farideh Najafi Co-Trustee

EXHIBIT A

Joint Filing Agreement

This Joint Filing Agreement is dated as of February 2, 2012 by and among Ramin Najafi, Ph.D., Farideh Najafi and the Najafi Family Trust.

WHEREAS, pursuant to Rule 240.13d-1(k) promulgated under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the parties hereto have decided to satisfy their filing obligations under the Exchange Act by a single joint filing;

NOW THEREFORE, the parties hereto agree as follows:

- 1. The Schedule 13G with respect to NovaBay Pharmaceuticals, Inc. to which this agreement is attached as Exhibit A (the "Schedule 13G") is filed on behalf of each of the parties hereto.
- 2. Each of the parties hereto is eligible to use the Schedule 13G.
- 3. Each of the parties hereto is responsible for the timely filing of the Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person or entity contained in the Schedule 13G; provided that each person or entity is not responsible for the completeness or accuracy of the information concerning any other person making such filing contained in the Schedule 13G, unless such person or entity knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the parties hereto have executed this Joint Filing Agreement as of the date first above written.

Ramin Najafi, Ph.D.

Farideh Najafi

NAJAFI FAMILY TRUST

By: Ramin Najafi, Ph.D. Co-Trustee

By: Farideh Najafi Co-Trustee